Establishing the reference interval for pulse oxygen saturation in neonates at high altitudes: protocol for a multicentre, open, cross-sectional study

Bo Wang, Chongde Liu, Yanli Yao, Zhihui Lu, Rong Yu, Zhuoma CaiRen, Zhixiu Wang, Runwu Liu, Yazhen Wu, Zhangbin Yu

ABSTRACT

Introduction Establishing the reference interval for pulse oxygen saturation (SpO2) is essential for sensitively identifying neonatal hypoxaemia due to various causes. However, the reference interval for high altitudes has not yet been established, and existing studies have many limitations. This study will aim to establish the reference interval for various high altitudes and determine whether preductal and postductal measurements at the same altitude vary.

Methods and analysis This is a multicentre, open, cross-sectional study, which will begin in February 2022. Approximately 2000 healthy full-term singleton neonates will be recruited from six hospitals (altitude ≥2000 m) in Qinghai Province, China. The participating hospitals will use a uniform pulse oximeter type. The measurements will be performed between 24 hours after birth and discharge. During the measurement, the neonate will be awake and quiet. Preductal and postductal measurements will be performed. The measurement time, site and results will be recorded and input, along with the collected basic information, into the perinatal cloud database. We will carry out strict quality control for basic information collection, measurement and data filing. We will perform descriptive statistics on the distribution range of the collected data, determine the lower limit value of the reference interval for each hospital and the corresponding altitude, perform curve fitting for the lower limit value, use the altitude as a covariate for the function corresponding to the fitted curve, establish the prediction equation and ultimately determine the reference intervals of each high altitude location.

Ethics and dissemination Our protocol has been approved by the Medical Ethics Committee of all participating hospitals. We will publish our study results in academic conferences and peer-reviewed public journals.

Trial registration number NCT05115721.

INTRODUCTION

Establishing the reference interval of neonatal pulse oxygen saturation (SpO2) is conducive to more sensitive identification of hypoxaemia due to sepsis, congenital heart disease and other causes. It could reduce the number of arterial blood gas samples and medical costs and improve the quality of nursing. The now widely used SpO2 reference interval for neonates 24 hours after birth has been developed based on data from low altitudes.4 It is not suitable for neonates at high altitudes because many studies have shown a downward trend in the mean SpO2 of neonates with the increase in altitude.5-11 Unfortunately, no reference interval has been established for high altitudes, and the existing studies on the topic have many limitations.

Obtaining accurate data from a suitable reference population is essential in determining reference intervals, requiring strict criteria to match the reference population characteristics to a normal or healthy population.12 However, previous studies were deficient in the selection of the reference populations. For example, a study conducted by Guo et al14 on neonates born at high altitudes found that the thresholds should be adjusted. However, their study population included premature infants. Another study, performed on a population at an altitude...
of 1371 to 2484 m, found a difference in SpO2 between preterm and full-term infants with no clinical symptoms and signs.13

Differences in measurement sites might contribute to differences in the results, an aspect many previous studies did not focus on.14 15 A multicentre large sample study from Yunnan, China, found significant differences between preductal and postductal measurements.11 However, the highest altitude in that study was only 2202 m. How the measurement site affects the results at higher altitudes needs further study.

Our previous study found only a few reports on the SpO2 of neonates 24 hours after birth in areas above 2000 m. We also noted that while these previous studies used the mean±SD to describe the results, their mean+2SD exceeded the theoretical maximum of 100%, indicating that their results were not normally distributed.16 IQRs should have been used so that reliable reference intervals could be derived. Furthermore, previous studies were often limited to a specific altitude. However, the SpO2 decreases with the increase in altitude,16 so the results of these studies can be applied to the specific altitude studied, while they cannot be generalised and applied to other altitudes.

We designed this multicentre, open, cross-sectional study to solve the many limitations of existing studies and establish the SpO2 reference interval for healthy neonates 24 hours after birth at several high altitudes. This study will provide the basis for neonatal care and medical decision making at high altitudes.

OBJECTIVE

The primary objective of this study is to establish the reference interval of SpO2 for healthy neonates 24 hours after birth at high altitudes.

The secondary objective of this study is to observe whether there are statistical differences between preductal and postductal measurements at the same altitude.

METHODS AND ANALYSIS

Study design

This is a multicentre, open, cross-sectional study, which will begin in February 2022. More than 2000 healthy neonates delivered consecutively will be recruited from six participating hospitals in Qinghai, China. This study protocol has been approved by the Medical Ethics Committee of all participating hospitals. All participating hospitals will be required to conduct the study in strict accordance with the established rules. Figure 1 presents a summary of the study process.

Jinan University designed and initiated the study, which is the affiliation body of the promoter (ZY). Qinghai Women and Children’s Hospital is the coordinating centre, the training centre and the affiliation body of the main verification person (CL). This is an open study. We welcome additional eligible hospitals to join this study.

Inclusion and exclusion criteria

Inclusion criteria are as follows:

Healthy singleton term infants (≥37 weeks) with no disease-related clinical signs or symptoms (e.g., cyanosis, respiratory distress, heart murmur).

Exclusion criteria are as follows:

1. Low birth weight (<2500 g).
2. Need for oxygen.
3. Apgar score <7 at 1 or 5 minutes.
4. Referred to neonatal intensive care unit or neonatology department for various reasons.
5. Discharged within 24 hours of birth.
6. With confirmed congenital disease in infants.
7. Refused participation.

The protocol was drafted in accordance with the recommended statement for standardised study protocol items: Recommendations for Observational Studies statement (online supplemental file 1).

Patient and public involvement

The guardians of the neonates and the public were not involved in the study and/or protocol design. Participation in this study will be entirely voluntary. The findings will be disseminated to the guardians and the public through popular science education, health brochures and academic conferences.

Participants

The six participating hospitals from Qinghai Province, China, form the Qinghai Plateau neonatal multicentre collaborative research group. Basic information of the participating hospitals is shown in Table 1. This study is planned to begin on 1 February 2022. Healthy neonates who meet the requirements will be consecutively recruited at the six participating hospitals and will undergo SpO2 measurements. The recruitment will be stopped when the sample size requirements are met at each altitude point. We expect the study will be completed within a year.

The infants clinical management will not be affected by whether their guardians decided to participate, refused participation or withdrew from the study.
Table 1 Participating hospitals basic information

| Hospital name                      | Altitude (m) | Number of infants delivered in 2020 |
|-----------------------------------|--------------|-------------------------------------|
| Qinghai University Affiliated Hospital | 2261         | 1356                                |
| Qinghai Red Cross Hospital        | 2261         | 8725                                |
| Qinghai Women and Children’s Hospital | 2261         | 1471                                |
| Geermu People’s Hospital           | 2808         | 1274                                |
| Yushu Prefecture People’s Hospital | 3680         | 2278                                |
| Guoluo Tibetan Autonomous Prefecture People’s Hospital | 4200 | 1403 |

5. Discharged within 24 hours of birth.
6. With confirmed congenital disease in utero.
7. Refused participation.

Informed consent
This study follows a completely voluntary principle. If consented, a written informed consent form will be signed by the subject’s guardian. The study complies with the Declaration of Helsinki. For details of the informed consent form, please refer to online supplemental file 2.

Collection of basic information
Information of the subject’s mother will include name, age, hospitalisation number, hospitalisation date, home address, telephone number and ethnicity.
Information on the infant will include name, date of birth, gestational age, sex, mode of delivery, birth weight and Apgar scores (1 and 5 min).

Definition standardisation
1. High altitude: at present, there is no unified standard classification of high altitude.14 Stanton et al defined high altitude as altitude greater than 1400 m,17 while Moore18 defined it as altitude greater than 2500 m. In this study, an altitude ≥2000 m is defined as high altitude.
2. Twenty-four hours after birth: ≥24 hours.
3. Measuring site: preductal SpO2 is the value measured on the right hand. Postductal SpO2 is the value measured on any foot.
4. The reference interval of SpO2 for neonates 24 hours after birth is defined as the lower limit value <SpO2≤100%. If the data do not conform to a normal distribution, the lower limit value will be defined as the value corresponding to the 2.5th percentile of the SpO2 distribution range in healthy neonates 24 hours after birth in the corresponding altitude. If the data are normally distributed, the lower limit value will correspond to the –2 SD value.11 19

Method of measurement
The neonate should be awake and quiet during the measurement, rather than crying or breast feeding. The measurement environment shall be a well-ventilated quiet room without strong light or electromagnetic field interference. The measurement will be performed between 24 hours after birth and discharge. When measuring, the probe will not be placed on the limbs that have just been used or are presently used to measure blood pressure. The surveyor will first clean the skin at the measuring site and keep it dry. The pulse oximeter’s special probe (sensor) will be wrapped around the neonate’s right hand and any foot. The measurement data of the two sites and the measurement time will be recorded after the SpO2 value and the signal waveform of the pulse oximeter were stable for at least 10s.

Standardised management of the operation
All participating hospitals will use the COVIDIEN 10005941SG pulse oximeter (Covidien Company, USA) with a reusable probe to measure SpO2. Each hospital shall select at least two full-time measuring operators. The coordination centre shall carry out standardised training for all measuring operators on 15 January 2022. Assessment will be conducted after training, and qualification will only be obtained after passing this assessment. The coordination centre will also provide standardised videos to all participating hospitals to facilitate repeated learning.

Each hospital will designate at least one high-level physician as the quality control person, who will conduct on-site operational inspections of the measuring personnel at least once a week in their respective hospitals. If the inspection finds that the operator was unqualified, the operator will be trained again. The coordination centre will conduct on-site inspections at least once a month in all hospitals to check whether the operation process and quality control were qualified.

Data collection
The data collected in this study will be divided into two parts, basic information data and measurement data. These data will be uploaded into the perinatal cloud database (https://www.perinatalcloud.com/) developed by the promoter (ZY). This database can be accessed to upload data from a computer or mobile phone at any time. See online supplemental file 3 for details of data collection.

Standardised management of data
The perinatal cloud database will be managed and operated by Jinan University to ensure data security. Each hospital has its independent account, and operators will only be able to browse and fill in their hospital’s data once logged in. Each subject will be given a unique number that will appear when analysing the data and issuing reports to protect the information of the subjects.
We established a data monitoring committee composed of research group chairpersons from the participating hospitals and the promoter. It has the authority to browse all the data and is responsible for monitoring the progress of the study to ensure compliance with the study plan. It will also recommend stopping further recruitment when the enrolment of a sufficient number of participants at a specific altitude has been met. The committee will hold regular quality control and analysis meetings to evaluate the study progress and whether there are any deviations from the protocol. The committee is also responsible for the overall sampling quality control, recruiting other participating hospitals, organising training, providing training materials, checking, collating and analysing the data and publishing the study results. If the study design needs to be changed, the committee should apply to the Medical Ethics Committee of Qinghai Women and Children’s Hospital for approval. The ethics committee is independent of sponsors, the promoter or any other entity that might influence their decisions. It is responsible for performing the annual audit of the study.

All collected data will be entered into the online database. See online supplemental file 4 for the specific login and filing steps. The data entry will be completed by the data entry personnel designated at each hospital. These personnel will be trained by the coordination centre and pass an examination before taking up their posts. We have adopted a three-level quality control method to ensure data input accuracy. Each hospital shall designate at least one first-class data quality controller responsible for checking each data entry. The coordination centre shall appoint secondary data quality controllers, one for each hospital. These will sample and inspect weekly at least 30% of the input data during that week. The third quality control level will be assumed by the data committee, which will sample and inspect monthly at least 10% of the input data. We have also established a WeChat group (an instant messaging application) in each hospital to disseminate timely feedback on the inspection results for rectification.

**Missing data or withdrawal from the trial**

We will apply strict quality control procedures during the data collection and filing process to ensure that no data will be missing from the database.

If a subject’s guardian requested to withdraw during or after the trial, we will fully respect this wish, withdraw the informed consent form, remove the information from the database and proceed to recruit new subjects.

**Sample size estimation**

The main statistical goal of this study is to establish reliable reference intervals. A large enough sample will be needed to generate precision estimates of extreme percentiles (such as the 2.5th percentile); however, there is no standard method for defining ‘precision’. Theoretically, the SpO₂ should show normal distribution when the sample size of such a cross-sectional study is large enough. We set the precision of this study, that is, the allowable error D, to 0.1 SD, using two-sided tests with α at 0.05. The required sample at each altitude was estimated by PASS V.15 at 387 infants. Moreover, we increased the sample size by 30% to reduce sampling errors and account for possible subject withdrawals, resulting in a sample size of 503 infants at each altitude. There is no need to expand the sample size by measuring site subgroups because preductal and postductal measurements will be performed on the same neonate. Because of the different volumes of infants delivered at each of the participating hospitals in 2020, we anticipate that the end of study at each altitude will occur at different time points. We expect this project will be completed within a year.

**Statistical analysis**

First, a normality test will be performed on the SpO₂ data at each altitude. If the data show normal distribution, the mean±SD will be used to describe the distribution of SpO₂. Paired-samples t-test will test for differences between the preductal and postductal data. If the two are statistically similar, the preductal and postductal data for each subject will be averaged, and then the lower limit value for the reference interval of each altitude will be determined. If the two measurements differ statistically, the lower limit value of the reference interval will be determined separately for preductal and postductal data at each altitude. If the data are not normally distributed, the median (IQR) will be used to describe SpO₂ distribution, and Wilcoxon signed-rank test will test for differences between the preductal and postductal measurements. The same principle will determine the lower limit value for the reference interval of each altitude.

After determining each lower limit value, we will visualise it using the altitude as the abscissa and SpO₂ as the ordinate to generate a curve fitting the data points. This will allow us to establish the function corresponding to a fitted curve that uses altitude as a covariate and the prediction equation for the reference interval lower limit value. The prediction equation will output the reference interval lower limit value by inputting the corresponding altitude. If the preductal and postductal will differ statistically, the prediction equation will be established separately for each.

Considering the Guoluo Tibetan Autonomous Prefecture People’s Hospital is located at a significantly higher altitude (4200 m) than other hospitals, we expect that the lower limit value of the reference interval at this location will be much lower, which may affect the fitting curve. Therefore, we will perform a subgroup analysis by excluding the data points obtained at this altitude. Finally, we will compare both analyses (ie, the one including and excluding the data points obtained at this altitude). Finally, we will compare both analyses (ie, the one including and excluding the data points obtained at this altitude) and select an appropriate curve to determine the optimal prediction equation.

All statistical tests will be two tailed, and p<0.05 will be considered significant. Statistical analysis will be performed using Stata V.16 and Python V.3.8.
DISCUSSION

SpO₂ is widely used in the field of neonatology. For example, many countries have included it in a routine screening programme for critical congenital heart disease.¹²⁻²⁰ However, a prerequisite for all these applications is to have a reliable reference interval. Rao et al.¹¹ used the standard low altitude interval, that is, 95%, as the threshold, to screen for congenital heart disease in infants at an altitude of 1646 m and found that the false-positive rate was 1.5%, much higher than in the low altitude population. The standard of low altitude is still being used during clinical assessments at high altitudes in China, resulting in misdiagnosing many healthy neonates as having hypoxaemia and the consequent huge waste of medical resources. This is one of the reasons we designed this study. Furthermore, this is the first multicentre investigation of SpO₂ reference interval in healthy neonates 24 hours after birth at high altitudes. We will establish a prediction equation to address the inability to establish a uniform reference interval because of the curvilinear decrease in the lower limit value of the SpO₂ reference interval with the increase in altitude.¹⁶

This project is a study on the SpO₂ of healthy neonates 24 hours after birth. The SpO₂ level fluctuates and is unstable during the first 24 hours after birth because it is the transition stage from fetal to neonatal circulation.²⁵ Several studies on the use of SpO₂ to screen congenital heart disease found that the false positive rate of measuring within 24 hours of birth was significantly higher than that 24 hours after birth, confirming that the SpO₂ level within the 24 hours of birth was unstable.²⁶⁻²⁸ Besides, we decided to not include multiple measurements after 24 hours of birth in our protocol. This is because: (1) at 24 hours after birth, the neonate has completed the transition from fetal circulation to neonatal circulation; therefore, at 24 hours after the birth of healthy neonates, the SpO₂ should be in a stable state; and (2) a large multicentre study of 41 097 measurements at altitudes ranging from 0 to 2500 m showed no differences in multiple SpO₂ measurements obtained from 24 hours after birth until discharge.¹¹ Therefore, our protocol focuses on personnel training and quality control to ensure that each SpO₂ measurement is accurate, rather than obtaining multiple measurements.

The measurements in this study will require the neonates to be awake and quiet. It will not consider measurements taken while the infants were asleep. This is because neonates are more prone to apnea or hypoventilation during sleep, resulting in transient periods of hypoxaemia, due to immature control of breathing, and higher compliance of the upper respiratory airway and chest resulting in lower respiratory reserve.²⁵ While these transient periods of neonatal hypoxaemia might be physiological phenomena, the value of SpO₂ measured in this case might be inaccurate, which is why our protocol excludes sleep periods.

This study hopes to determine the reference interval at high altitudes by formulating a predictive equation. Theoretically, the precision of the curve fitting to the data points increases with the distribution of the points through various altitudes, resulting in a more accurate predictive equation. The limitation of this study is that thus far, we have recruited only six hospitals at four altitudes, possibly limiting the accuracy of the prediction equation to be generated. We continue to recruit hospitals at other altitudes to address this limitation.

In conclusion, the results of our study will help medical staff identify hypoxaemia in neonates at high altitudes with higher sensitivity, reducing the misdiagnosis rate and medical burden. It will also provide a theoretical basis for determining thresholds to be used when screening for ailments such as congenital heart disease.

ETHICS AND DISSEMINATION

Each participating hospital should be approved by the local Ethics Committee, and the proof of local approval must be sent to the coordinating centre before recruitment can begin at each hospital. Currently, our protocol has been approved by the Medical Ethics Committee of the six participating hospitals. The staff involved will give a detailed explanation to the guardians of all subjects to ensure they have a comprehensive understanding of the study. Written material will also be provided. If they agree to participate, the guardians will sign informed consent forms. Strict confidentiality will be applied to all data collected. The results of this study will be published in academic conferences and peer-reviewed public journals.

Author affiliations
¹Department of Pediatrics, Suqian First People’s Hospital, Suqian, Jiangsu, China
²Department of Neonatology, Qinghai Women and Children’s Hospital, Xining, Qinghai, China
³Department of Neonatology, Qinghai Red Cross Hospital, Xining, Qinghai, China
⁴Department of Obstetrics and Gynecology, Qinghai University Affiliated Hospital, Xining, Qinghai, China
⁵Department of Neonatology, Geermu People’s Hospital, Geermu, Qinghai, China
⁶Department of Neonatology, Yushu Prefecture People’s Hospital, Yushu Tibetan Autonomous Prefecture, Qinghai, China
⁷Department of Neonatology, Guoluo Tibetan Autonomous Prefecture People’s Hospital, Guoluo Tibetan Autonomous Prefecture, Qinghai, China
⁸Department of Neonatology, Qinghai Women and Children’s Hospital, Xining, Qinghai, China
⁹Department of Neonatology, Guoluo Tibetan Autonomous Prefecture People’s Hospital, Guoluo Tibetan Autonomous Prefecture, Qinghai, China
10Department of Neonatology, Shenzhen People’s Hospital, Shenzhen, Guangdong, China

Contributors ZY and CL planned the study. ZY and BW designed the study. CL provided ethical support. ZY and BW registered the study. ZY is the promoter. CL is the main coordinator and the main verifier. BW, YY, ZL and YW wrote the study protocol and revised the manuscript. RY, ZC, ZW and RL performed a critical revision of the manuscript. ZY and BW performed the statistical analysis. All the authors read and approved the final version.

Funding This study has been supported by Key Research and Development Plan (Social Development) of Jiangsu Province (grant number BE2019620).

Disclaimer The funding body play no role in design and management of the study, collection, analysis and interpretation of data and manuscript preparation.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Patient consent for publication Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ID
Bo Wang http://orcid.org/0000-0001-8916-3049

REFERENCES
1. Tekleab AM, Sewnet YC. Role of pulse oximetry in detecting critical congenital heart disease among newborns delivered at a high altitude setting in Ethiopia. Pediatr Health Med Ther 2019;10:83–8.
2. Roizen MF, Schreider B, Austin W, et al. Pulse oximetry, capnography, and blood gas measurements: reducing cost and improving the quality of care with technology. J Clin Monit 1993;3:237–40.
3. Kellerman AL, Cofer CA, Joseph S, et al. Impact of portable pulse oximetry on arterial blood gas test ordering in an urban emergency department. Ann Emerg Med 1991;20:130–40.
4. Hoffman JIE. Is pulse oximetry useful for screening neonates for critical congenital heart disease at high altitudes? Pediatr Cardiol 2016;37:812–7.
5. Thilo EH, Park-Moore B, Berman ER, et al. Oxygen saturation by pulse oximetry in healthy infants at an altitude of 1610 m (5280 ft). What is normal? Am J Dis Child 1991;145:1137–40.
6. Niermeyer S, Shaffer EM, Thilo E, et al. Arterial oxygenation and pulmonary arterial pressure in healthy neonates and infants at high altitude. J Pediatr 1993;123:767–72.
7. Tapia-Rombo CA, Rosales-Cervantes MGI, Saucedo-Zavala VJ, et al. [Oxygen peripheral saturation using pulse oximetry among healthy term newborns at Mexico's altitude (2240 m)]. Gac Med Mex 2008;144:207–12.
8. Han LM, Kleweer SE, Blank KM, et al. Feasibility of pulse oximetry screening for critical congenital heart disease at 2643-foot elevation. Pediatr Cardiol 2013;34:1803–7.
9. Samuel TY, Bromiker R, Mimouni FB, et al. Newborn oxygen saturation at mild altitude versus sea level: implications for neonatal screening for critical congenital heart disease. Acta Paediatr 2013;102:379–84.
10. González-Andrade F, Echeverría D, López V, et al. Is pulse oximetry helpful for the early detection of critical congenital heart disease at high altitude? Congenit Heart Dis 2018;13:911–8.
11. Guo F, Tang S, Guo T, et al. Revised threshold values for neonatal oxygen saturation at mild and moderate altitudes. Acta Paediatr 2020;109:321–6.
12. Hoq M, Kariaftis V, Mathews S, et al. A prospective, cross-sectional study to establish age-specific reference intervals for neonates and children in the setting of clinical biochemistry, immunology and haematology; the HAPPI kids study protocol. BMJ Open 2019;9:e025897.
13. Ravert P, Dettwiler TL, Dickinson JK. Mean oxygen saturation in well neonates at altitudes between 4498 and 8150 feet. Adv Neonatal Care 2011;11:412–7.
14. Bakr AF, Habib HS. Normal values of pulse oximetry in newborns at high altitude. J Trop Pediatr 2005;51:170–3.
15. Salas AA. Pulse oximetry values in healthy term newborns at high altitude. Ann Trop Paediatr 2008;28:275–8.
16. Wang B, Zhang J, Wu Y-Z, et al. Reference interval for pulse oxygen saturation in neonates at different altitudes: a systematic review. Front Pediatr 2021;9:771750.
17. Stanton MC, Adriko M, Arinaitwe M, et al. Intestinal schistosomiasis in Uganda at high altitude (>1400 m): malacological and epidemiological surveys on Mount Elgon and in Fort Portal crater lakes reveal extra preventive chemotherapy needs. Infect Dis Poverty 2017:8:34.
18. Moore LG. Human genetic adaptation to high altitude. High Alt Med Biol 2001;2:257–79.
19. Tian YP, Hu XJ, Ma XJ, et al. [The distribution and variance of neonatal pulse oxygen saturation at different altitudes]. Zhonghua Yi Xue Za Zhi 2021;101:1410–4.
20. Altman DG, Ohuma EO, International Fetal and Newborn Growth Consortium for the 21st Century. Statistical considerations for the development of prescriptive fetal and newborn growth standards in the INTERGROWTH-21st project. BJOG 2013;120(Suppl 2):S7–61.
21. Kemper AR, Mahle WT, Martin GR, et al. Strategies for implementing screening for congenital heart disease. Pediatrics 2011;128:e1259–67.
22. Singh A, Ewer AK. Pulse oximetry screening for critical congenital heart defects: a UK national survey. Lancet 2013;381:535.
23. Zhao Q-ming, Ma X-jing, Ge X-ling, et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet 2014;384:747–54.
24. Ruo S, Goens MB, Myers OB, et al. Pulse oximetry screening for detection of congenital heart defects at 1646 m in Albuquerque, New Mexico. Cardiol Young 2020;30:1851–5.
25. Morgan MC, Maina B, Waiyego M, et al. Oxygen saturation ranges for healthy newborns within 24 hours at 1800 m. Arch Dis Child Fetal Neonatal Ed 2017;102:F266–8.
26. Thangaratnam S, Brown K, Zamora J, et al. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis. Lancet 2012;379:2459–64.
27. Jullien S. Newborn pulse oximetry screening for critical congenital heart defects. BMC Pediatr 2021;21:305.
28. Plana MN, Zamora J, Suresh G, et al. Pulse oximetry screening for critical congenital heart defects. Cochrane Database Syst Rev 2018;3:CD011912.
29. Daftary AS, Jalou HE, Shively L, et al. Polysomnography reference values in healthy newborns. J Clin Sleep Med 2019;15:437–43.